Revolution Medicines reports promising early data for KRAS drug combo, plans Phase 3 in pancreatic cancer

Revolution Medicines presented early-stage results that support moving forward with a Phase 3 study of a combination of two KRAS-targeted agents in pancreatic cancer.

The data, shown for the first time, indicated that the dual approach may improve efficacy compared with each drug alone, according to the company’s briefing.

Based on these findings, the company announced plans to launch a pivotal Phase 3 trial to further evaluate the safety and benefit of the combination in patients with KRAS-mutated pancreatic tumors.

The announcement highlights the continued focus on targeting KRAS mutations, a long-standing challenge in oncology, and underscores the potential for new therapeutic options in a disease with limited treatment success.